Eli Lilly raises forecasts on surging demand for weight-loss, diabetes drugs

Eli Lilly's Q3 earnings surpass expectations, driven by robust sales of Zepbound and Mounjaro, propelling the company ahead in the competitive weight-loss drug market. Despite investor caution due to U.S. drug price negotiations, Lilly raises its profit and revenue outlook for the year, with analysts predicting profits of around $23.70 per share and revenue of $63.5 billion. Novo Nordisk's earnings report on November 5th will determine if they can maintain the pace.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.